LOGIN  |  REGISTER
Assertio

Amwell to participate in upcoming investor conferences

October 28, 2024 | Last Trade: US$10.97 0.68 6.61

BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital care, announced company leaders will participate in several upcoming investor conferences. Ido Schoenberg, M.D., Amwell chairman and chief executive officer, and Mark Hirschhorn, Amwell chief financial officer, will participate in fireside chats or one-on-one meetings at these events:

  • Nov. 12: UBS Global Healthcare Conference in Palos Verdes, Calif. The fireside chat is at 8:45 a.m. PT.
  • Nov. 20: Needham 4th Annual Consumer Tech Conference. Virtual one-on-one meetings throughout the day.
  • Nov. 25: The BTIG Virtual Health Forum. Virtual one-on-one meetings throughout the day.
  • Dec. 4: The Piper Sandler 36th Annual Healthcare Conference in New York. The fireside chat time will be determined at a later date.

An audio webcast of the fireside chats will be available at investors.amwell.com.

About Amwell  

Amwell is a leading hybrid care delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.

©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, Amwell Converge™, Carepoint™ and the Amwell Logo are registered trademarks of American Well Corporation.

Recursion

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page